Understanding the mechanism of 5-ASA in treating colonic inflammation

Gastroenterology and Hepatology

Volumn 4, Issue 5, 2008, Pages 319-320

  Desreumaux, Pierre ^a  

^a UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; GED 0507 34; GLITAZONE DERIVATIVE; MESALAZINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANTIINFLAMMATORY ACTIVITY; COLITIS; CROHN DISEASE; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENTERITIS; GENE EXPRESSION REGULATION; HUMAN; INTESTINE FLORA; NONHUMAN; NOTE; RECEPTOR AFFINITY; RECEPTOR DOWN REGULATION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 44449150242     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (5)

1. Linard C, Gremy O, Benderitter M. Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist. J Pharmacol Exp Ther. 2008;324:911-920.
2. Desreumaux P, Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther. 2006;24(Suppl 1):2-9.
3. Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, et al. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut. 2006;55:1341-1349.
4. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med. 2005;201:1205-1215.
5. Alarcon de la Lastra C, Sanchez-Fidalgo S, Villegas I, Motilva V. New pharmacological perspectives and therapeutic potential of PPAR-gamma agonists. Curr Pharm Des. 2004;10:3505-3524.